Zobrazeno 1 - 10 of 33 pro vyhledávání: '"SM Lougheed"'
2
Akademický článek
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition.
Autor: van den Ende T; Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands., Ezdoglian A; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Baas LM; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Bakker J; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Lougheed SM; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Harrasser M; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Waasdorp C; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., van Berge Henegouwen MI; Department of Surgery, Amsterdam Umc, University of Amsterdam, Amsterdam, The Netherlands.; Cancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands., Hulshof MCCM; Cancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Department of Radiotherapy, Amsterdam Umc, University of Amsterdam, Amsterdam, The Netherlands., Haj Mohammad N; Department of Medical Oncology, UMC Utrecht, Utrecht University, Utrecht, The Netherlands., van Hillegersberg R; Department of Surgery, UMC Utrecht, Utrecht University, Utrecht, The Netherlands., Mook S; Department of Radiotherapy, UMC Utrecht, Utrecht University, Utrecht, The Netherlands., van der Laken CJ; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands., van Grieken NCT; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.; Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Derks S; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Bijlsma MF; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., van Laarhoven HWM; Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands., de Gruijl TD; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
Publikováno v: Oncoimmunology [Oncoimmunology] 2023 Jul 17; Vol. 12 (1), pp. 2233403. Date of Electronic Publication: 2023 Jul 17 (Print Publication: 2023).
Zobrazit plný text záznamu
3
Akademický článek
A Reconstructed Human Melanoma-in-Skin Model to Study Immune Modulatory and Angiogenic Mechanisms Facilitating Initial Melanoma Growth and Invasion.
Autor: Michielon E; Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Location Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.; Amsterdam Institute for Infection and Immunity, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, 1081 HV Amsterdam, The Netherlands., López González M; Amsterdam Institute for Infection and Immunity, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, 1081 HV Amsterdam, The Netherlands.; Department of Medical Oncology, Amsterdam UMC, Location Vrije Universiteit, 1105 AZ Amsterdam, The Netherlands., Stolk DA; Amsterdam Institute for Infection and Immunity, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, 1081 HV Amsterdam, The Netherlands.; Department of Medical Oncology, Amsterdam UMC, Location Vrije Universiteit, 1105 AZ Amsterdam, The Netherlands., Stolwijk JGC; Amsterdam Institute for Infection and Immunity, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, 1081 HV Amsterdam, The Netherlands.; Department of Medical Oncology, Amsterdam UMC, Location Vrije Universiteit, 1105 AZ Amsterdam, The Netherlands., Roffel S; Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Location Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.; Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit, 1105 AZ Amsterdam, The Netherlands., Waaijman T; Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Location Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.; Amsterdam Institute for Infection and Immunity, 1105 AZ Amsterdam, The Netherlands., Lougheed SM; Amsterdam Institute for Infection and Immunity, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, 1081 HV Amsterdam, The Netherlands.; Department of Medical Oncology, Amsterdam UMC, Location Vrije Universiteit, 1105 AZ Amsterdam, The Netherlands., de Gruijl TD; Amsterdam Institute for Infection and Immunity, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, 1081 HV Amsterdam, The Netherlands.; Department of Medical Oncology, Amsterdam UMC, Location Vrije Universiteit, 1105 AZ Amsterdam, The Netherlands., Gibbs S; Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Location Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.; Amsterdam Institute for Infection and Immunity, 1105 AZ Amsterdam, The Netherlands.; Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit, 1105 AZ Amsterdam, The Netherlands.
Publikováno v: Cancers [Cancers (Basel)] 2023 May 20; Vol. 15 (10). Date of Electronic Publication: 2023 May 20.
Zobrazit plný text záznamu
4
Akademický článek
Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T reg reduction and effector T cell activation.
Autor: van Pul KM; Amsterdam UMC location Vrije Universiteit, Medical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.; Amsterdam UMC location Vrije Universiteit, Surgical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunology, Cancer Immunology, Amsterdam, Netherlands., Notohardjo JCL; Amsterdam UMC location Vrije Universiteit, Medical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunology, Cancer Immunology, Amsterdam, Netherlands., Fransen MF; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunology, Cancer Immunology, Amsterdam, Netherlands.; Amsterdam UMC location Vrije Universiteit, Pulmonary Diseases, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands., Koster BD; Amsterdam UMC location Vrije Universiteit, Medical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunology, Cancer Immunology, Amsterdam, Netherlands., Stam AGM; Amsterdam UMC location Vrije Universiteit, Medical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunology, Cancer Immunology, Amsterdam, Netherlands., Chondronasiou D; Amsterdam UMC location Vrije Universiteit, Medical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunology, Cancer Immunology, Amsterdam, Netherlands., Lougheed SM; Amsterdam UMC location Vrije Universiteit, Medical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunology, Cancer Immunology, Amsterdam, Netherlands., Bakker J; Amsterdam UMC location Vrije Universiteit, Medical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunology, Cancer Immunology, Amsterdam, Netherlands., Kandiah V; Amsterdam UMC location Vrije Universiteit, Medical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunology, Cancer Immunology, Amsterdam, Netherlands., van den Tol MP; Amsterdam UMC location Vrije Universiteit, Surgical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunology, Cancer Immunology, Amsterdam, Netherlands., Jooss K; Pfizer Inc., San Diego, CA, USA., Vuylsteke RJCLM; Department of Surgical Oncology, Spaarne Gasthuis, Boerhaavelaan 22, 2035 RC, Haarlem, Netherlands., van den Eertwegh AJM; Amsterdam UMC location Vrije Universiteit, Medical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunology, Cancer Immunology, Amsterdam, Netherlands., de Gruijl TD; Amsterdam UMC location Vrije Universiteit, Medical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunology, Cancer Immunology, Amsterdam, Netherlands.
Publikováno v: Science immunology [Sci Immunol] 2022 Jul 15; Vol. 7 (73), pp. eabn8097. Date of Electronic Publication: 2022 Jul 15.
Zobrazit plný text záznamu
5
Akademický článek
Loss of FLCN-FNIP1/2 induces a non-canonical interferon response in human renal tubular epithelial cells.
Autor: Glykofridis IE; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Cancer Center Amsterdam, Amsterdam, Netherlands., Knol JC; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands., Balk JA; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Cancer Center Amsterdam, Amsterdam, Netherlands., Westland D; University Medical Center Utrecht, Center for Molecular Medicine, Molecular Cancer Research, Universiteitsweg, Utrecht, Netherlands., Pham TV; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands., Piersma SR; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands., Lougheed SM; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands., Derakhshan S; Princess Máxima Center for Pediatric Oncology, Oncode Institute, Heidelberglaan, Utrecht, Netherlands., Veen P; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Cancer Center Amsterdam, Amsterdam, Netherlands., Rooimans MA; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Cancer Center Amsterdam, Amsterdam, Netherlands., van Mil SE; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Cancer Center Amsterdam, Amsterdam, Netherlands., Böttger F; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands., Poddighe PJ; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Amsterdam, Netherlands., van de Beek I; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Amsterdam, Netherlands., Drost J; Princess Máxima Center for Pediatric Oncology, Oncode Institute, Heidelberglaan, Utrecht, Netherlands., Zwartkruis FJ; University Medical Center Utrecht, Center for Molecular Medicine, Molecular Cancer Research, Universiteitsweg, Utrecht, Netherlands., de Menezes RX; NKI-AvL, Biostatistics Unit, Amsterdam, Netherlands., Meijers-Heijboer HE; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Cancer Center Amsterdam, Amsterdam, Netherlands., Houweling AC; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Amsterdam, Netherlands., Jimenez CR; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands., Wolthuis RM; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Cancer Center Amsterdam, Amsterdam, Netherlands.
Publikováno v: ELife [Elife] 2021 Jan 18; Vol. 10. Date of Electronic Publication: 2021 Jan 18.
Zobrazit plný text záznamu
6
Akademický článek
Adenocarcinoma of the Uterine Cervix Shows Impaired Recruitment of cDC1 and CD8 + T Cells and Elevated β-Catenin Activation Compared with Squamous Cell Carcinoma.
Autor: Rotman J; Cancer Center Amsterdam (CCA), Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands., Heeren AM; Cancer Center Amsterdam (CCA), Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands., Gassama AA; Cancer Center Amsterdam (CCA), Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands., Lougheed SM; Cancer Center Amsterdam (CCA), Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands., Pocorni N; Cancer Center Amsterdam (CCA), Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands., Stam AGM; Cancer Center Amsterdam (CCA), Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands., Bleeker MCG; Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands., Zijlmans HJMAA; Center for Gynecologic Oncology Amsterdam (CGOA), The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, the Netherlands., Mom CH; Cancer Center Amsterdam (CCA), Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands.; Cancer Center Amsterdam (CCA), Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands., Kenter GG; Cancer Center Amsterdam (CCA), Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands.; Center for Gynecologic Oncology Amsterdam (CGOA), The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, the Netherlands., Jordanova ES; Cancer Center Amsterdam (CCA), Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands.; Cancer Center Amsterdam (CCA), Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands.; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands., de Gruijl TD; Cancer Center Amsterdam (CCA), Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands. TD.deGruijl@amsterdamumc.nl.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Jul 15; Vol. 26 (14), pp. 3791-3802. Date of Electronic Publication: 2020 Mar 27.
Zobrazit plný text záznamu
7
Akademický článek
Constitutively active GSK3β as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression.
Autor: López González M; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands., Oosterhoff D; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands., Lindenberg JJ; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands., Milenova I; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands., Lougheed SM; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands., Martiáñez T; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands., Dekker H; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Hangalapura B; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands., Joore J; PepScope B.V., VB Utrecht, Netherlands., Piersma SR; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Scheper RJ; Department of Pathology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands., Verheul HMW; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands., Jiménez CR; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands., Van De Ven R; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.; Department Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Van Beusechem VW; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands., De Gruijl TD; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands.
Publikováno v: Oncoimmunology [Oncoimmunology] 2019 Jul 19; Vol. 8 (10), pp. e1631119. Date of Electronic Publication: 2019 Jul 19 (Print Publication: 2019).
Zobrazit plný text záznamu
8
Akademický článek
Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.
Autor: Werter IM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centre, VU University Medical Centre, Vrije University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. i.werter@vumc.nl., Huijts CM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centre, VU University Medical Centre, Vrije University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Lougheed SM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centre, VU University Medical Centre, Vrije University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Hamberg P; Department of Medical Oncology, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands., Polee MB; Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Tascilar M; Department of Medical Oncology, Isala Clinics, Zwolle, The Netherlands., Los M; Department of Medical Oncology, Saint Antonius Hospital, Nieuwegein, The Netherlands., Haanen JBAG; Department of Medical Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Helgason HH; Department of Medical Oncology, Haaglanden Medical Centre, The Hague, The Netherlands., Verheul HM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centre, VU University Medical Centre, Vrije University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., de Gruijl TD; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centre, VU University Medical Centre, Vrije University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., van der Vliet HJ; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centre, VU University Medical Centre, Vrije University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. jj.vandervliet@vumc.nl.
Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2019 May; Vol. 68 (5), pp. 787-798. Date of Electronic Publication: 2019 Feb 11.
Zobrazit plný text záznamu
9
Akademický článek
The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.
Autor: Huijts CM; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. c.huijts@vumc.nl., Lougheed SM; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Bodalal Z; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., van Herpen CM; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Hamberg P; Department of Medical Oncology, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands., Tascilar M; Department of Medical Oncology, Isala Clinics, Zwolle, The Netherlands., Haanen JB; Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Verheul HM; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., de Gruijl TD; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., van der Vliet HJ; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. jj.vandervliet@vumc.nl.
Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2019 Mar; Vol. 68 (3), pp. 503-515. Date of Electronic Publication: 2019 Jan 17.
Zobrazit plný text záznamu
10
Akademický článek
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.
Autor: Huijts CM; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. c.huijts@vumc.nl., Werter IM; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Lougheed SM; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Goedegebuure RS; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., van Herpen CM; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Hamberg P; Department of Medical Oncology, Franciscus Gasthuis, Rotterdam, The Netherlands., Tascilar M; Department of Medical Oncology, Isala Clinics, Zwolle, The Netherlands., Haanen JB; Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Verheul HM; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., de Gruijl TD; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., van der Vliet HJ; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. jj.vandervliet@vumc.nl.
Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2019 Feb; Vol. 68 (2), pp. 319-329. Date of Electronic Publication: 2018 Nov 09.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje